Highly pathogenic Influenza A H5N1 was first identified in Guangdong Province in 1996, followed by human cases in Hong Kong in 1997 1 . The number of confirmed human cases now exceeds 300 and the associated Case Fatality Rate exceeds 60% 2 . The genetic diversity of the serotype continues to increase. Four distinct clades or sub-clades have been linked to human cases 3.4 . The gradual genetic changes identified in the sub-clades have been attributed to copy errors by viral encoded polymerases that lack an editing function, thereby resulting in antigenic drift 5 . We traced polymorphism acquisition in Clade 2.2 sequences. We report here the concurrent acquisition of the same polymorphism by multiple, genetically distinct, Clade 2.2 sub-clades in Egypt, Russia and Ghana. These changes are not easily explained by the current theory of "random mutation" through copy error, and are more easily explained by recombination with a common source. This conclusion is supported by additional polymorphisms shared by Clade 2.2 isolates in Egypt, Nigeria and Germany including aggregation of regional polymorphisms from each of these areas into a single Nigerian human hemagglutinin gene.
The study of influenza evolution in nature has been aided by the emergence of a new strain (Clade 2.2) first identified at Qinghai Lake in central China in the spring of 2005. Sequencing of all eight genes 6, 7 showed that isolates from migratory waterfowl were easily distinguishable from previous isolates linked to poultry and human infections in eastern and southeastern Asia. Additional HA polymorphisms are noted in the HA phylogram (data not shown).
Isolates that had the NA polymorphism, G743A, also had a synonymous HA polymorphism, C689T. This polymorphism was also in human and bird isolates from the Nile Delta. Another polymorphism, G754A, that encodes M230I, is in one of the German isolates The individual polymorphisms recombine to generate sequences that create antigenic drift. Mapping of these pathways and associations can be used to develop novel vaccine targets representing rapidly evolving genomes.
